NUALS Arts and Literary Annual Meet

Syntec Optics, Inc., a Leading Advanced Manufacturing Company, Completes Business Combination with OmniLit (Nasdaq:OLIT) and Will Commence Trading on Nasdaq Under Ticker Symbol “OPTX”

Retrieved on: 
Tuesday, November 7, 2023
NUALS Arts and Literary Annual Meet, OLIT, Annual, Annual general meeting, Cryptocurrency, Syntec

The combined company will operate under the name Syntec Optics Holdings, Inc. (“Syntec” and the “Company”).

Key Points: 
  • The combined company will operate under the name Syntec Optics Holdings, Inc. (“Syntec” and the “Company”).
  • The company will continue to be led by Joe Mohr, Chief Executive Officer, alongside the rest of the current Syntec management team.
  • Over 99.9% of the votes cast on the business combination proposal at the Annual Meeting were cast in favor of approving the business combination.
  • “We are excited to begin the next chapter of Syntec’s story,” said Joe Mohr, Chief Executive Officer of Syntec Optics.

Oil-Dri to Host First Quarter 2024 Earnings Discussion and Fiscal Year 2023 Annual Meeting of Stockholders via Live Webcast

Retrieved on: 
Monday, October 30, 2023
NYSE, NUALS Arts and Literary Annual Meet, Research, Archive, Marketing, Annual, Webcast, Central Time, ODC, Journal of Creating Value, Shareholder

The Company will host its first quarter fiscal 2024 earnings discussion and its Annual Meeting of Stockholders virtually via a live webcast on Wednesday, December 13, 2023 at 9:30 am Central Time.

Key Points: 
  • The Company will host its first quarter fiscal 2024 earnings discussion and its Annual Meeting of Stockholders virtually via a live webcast on Wednesday, December 13, 2023 at 9:30 am Central Time.
  • The record date for voting eligibility at the Annual Meeting was Monday, October 16, 2023.
  • Participation details can be found on Oil-Dri’s website’s Events page, and the webcast will be available for replay.
  • With over 80 years of experience, the Company continues to fulfill its mission to Create Value from Sorbent Minerals.

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 2, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, Insurance, MSCE, ATM, FINANCIAL, MPH, Medication, Development of the human body, American Epilepsy Society, MD, Children's Hospital of Philadelphia, Dravet syndrome, SAD, Lennox–Gastaut syndrome, Caregiver, Clinical trial, Longboard, DSM-IV codes, NUALS Arts and Literary Annual Meet, Philadelphia, AES, Pacific studies, Investment, Hospital, DEE, Child, Pharmaceutical industry

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023.
  • “We look forward to PACIFIC Study topline data in January 2024 evaluating LP352 in people living with Developmental and Epileptic Encephalopathies, or DEEs.
  • DEE caregivers and healthcare providers continue to be frustrated with the lack of new treatment options and remain focused on finding treatment options that balance safety, efficacy and burden.
  • We look forward to Phase 1 SAD data in the first half of 2024,” stated Kevin R. Lind, Longboard’s President and Chief Executive Officer.

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

Retrieved on: 
Thursday, November 2, 2023
Survival, Aes, Johns Hopkins University, NUALS Arts and Literary Annual Meet, Publication, Maintenance, Ipilimumab, Necrosis, Nausea, Poster, Clinical trial, Neoplasm, Cancer, Annual general meeting, Safety, Therapy, Patient, Intensity, Sarcoma, Fatigue, Pharmaceutical industry, Birth control

WESTPORT, Conn., Nov. 2, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that safety, tolerability and efficacy data from IT-01, the company's ongoing Phase 1/2 clinical trial of INT230-6, either as a monotherapy or in combination with ipilimumab in patients with relapsed, refractory and metastatic sarcomas, was presented at the Connective Tissue Oncology Society 2023 Annual Meeting being held in Dublin, Ireland from November 1-4, 2023. The poster will be displayed for the duration of the Annual Meeting.

Key Points: 
  • Christian Frederick Meyer , M.D., Ph.D., M.S., is an Assistant Professor of Oncology at the Sidney Kimmel Cancer Center at Johns Hopkins University.
  • Dr. Meyer is an investigator for Intensity's Phase 1/2 clinical trial of INT230-6 and the presenter of the data at CTOS.
  • Dr. Meyer has placed a number of his sarcoma patients into the study due to the demonstrated significant survival prolongation effects of INT230-6.
  • When compared to synthetic controls, INT230-6 alone extended survival in refractory soft tissue sarcoma subjects by approximately 14.9 months.

Unrivaled Brands Files S-4; Announces Corporate Reorganization to become Blüm

Retrieved on: 
Tuesday, October 10, 2023
Annual general meeting, OTCQB, Reverse stock split, Proxy, Prospectus, Form, Corporate action, NUALS Arts and Literary Annual Meet, Exchange, Securities and Exchange Commission (Philippines), Sale, WHEN, Suite, Security (finance), Holding company, Unrivaled, Shareholder

SANTA ANA, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Unrivaled Brands, Inc. (OTCQB: UNRV) (“Unrivaled,” “Unrivaled Brands,” or the “Company”), a Nevada cannabis company with operations throughout California, announced today that it intends to implement a reorganization in which a new Delaware holding company, Blum Holdings, Inc. (“Blüm”), would become the publicly traded holding company of Unrivaled Brands and its subsidiaries (the “Reorganization”).

Key Points: 
  • SANTA ANA, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Unrivaled Brands, Inc. (OTCQB: UNRV) (“Unrivaled,” “Unrivaled Brands,” or the “Company”), a Nevada cannabis company with operations throughout California, announced today that it intends to implement a reorganization in which a new Delaware holding company, Blum Holdings, Inc. (“Blüm”), would become the publicly traded holding company of Unrivaled Brands and its subsidiaries (the “Reorganization”).
  • Any outstanding securities convertible or exercisable for shares of Unrivaled common stock will become securities convertible or exercisable for shares of Blüm common stock.
  • In connection with the Reorganization, Blüm has filed a registration statement on Form S-4 that includes a preliminary proxy statement of Unrivaled Brands and a preliminary prospectus of Blüm, and Unrivaled Brands and Blüm may file with the SEC other relevant documents in connection with the proposed Reorganization.
  • Unrivaled Brands and its directors, executive officers and certain other members of management and employees may be deemed to be participants in the solicitation of proxies from Unrivaled Brands’ stockholders in connection with the Reorganization.

OmniLit Acquisition Corp. (Nasdaq: OLIT) Announces Effectiveness of Registration Statement and October 31, 2023 Annual Meeting of Stockholders to Approve Business Combination with Syntec Optics, Inc.

Retrieved on: 
Friday, October 6, 2023
Transfer, Annual general meeting, Proxy statement, Acquisition, Internet, Bangladesh Securities and Exchange Commission, OLIT, Health, Proxy, Form, NUALS Arts and Literary Annual Meet, MIAMI, Annual, Auction, Holding company

Syntec Optics is a leading optics and photonics company for scientific and technical instruments, and aerospace and defense.

Key Points: 
  • Syntec Optics is a leading optics and photonics company for scientific and technical instruments, and aerospace and defense.
  • OmniLit will mail the definitive proxy statement/prospectus (the “Proxy Statement”) to stockholders of record as of the close of business on October 6, 2023.
  • The Proxy Statement contains a notice and voting instruction form or a proxy card relating to the special meeting of OmniLit’s stockholders (the “Annual Meeting”).
  • The Annual Meeting to approve the proposed business combination is scheduled to be held on October 31, 2023 at 11:00 a.m. Eastern Time via a virtual meeting format at https://www.colonialstock.com/omnilitacquisition.

Together with Siemens Healthineers, Varian Demonstrates Commitment to Embracing Innovation and Enhancing Outcomes at ASTRO 2023

Retrieved on: 
Thursday, September 28, 2023
Ethos, Eclipse, Graphics processing unit, Communication, ECLIPSE, CBCT, KG, Annual, NUALS Arts and Literary Annual Meet, Cancer, Quality of life, EDGE, Radiation therapy, Medical examiner, Sale, ARIA, Siemens Healthineers, Radiation, Acquisition, Patient, Automation, Standard of care, User, FDA, RT, American Society for Radiation Oncology, Society, Medical imaging, Nursing, Medical device, ASTRO, Varian

PALO ALTO, Calif., Sept. 28, 2023 /PRNewswire/ -- Varian, a Siemens Healthineers company, is showcasing technologies that reflect its continued commitment to embracing innovation and enhancing outcomes for cancer patients at this year's 2023 American Society for Radiation Oncology (ASTRO) annual meeting, taking place from October 1-4 in San Diego, California.

Key Points: 
  • The solutions Varian will be highlighting at ASTRO support the company's commitment to embracing innovation and enhancing outcomes by:
    By joining forces with Siemens Healthineers, a global leader in imaging, Varian is working to expand its imaging capabilities to provide solutions with improved accuracy and quality.
  • Varian is pioneering integrated software solutions to reduce redundancies and streamline workflows to unify patient care pathways and ultimately improve outcomes.
  • VARIAN, ARIA, ECLIPSE, ETHOS, HYPERSIGHT, EDGE, and TRUEBEAM are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat.
  • Siemens Healthineers is a trademark of Siemens Trademark GmbH & Co. KG registered U.S. Pat.

NorthWest Copper Announces Results of AGM

Retrieved on: 
Wednesday, September 27, 2023
Interim, TSX Venture Exchange, Geology, First Nations, NUALS Arts and Literary Annual Meet, Risk, Mining, Annual general meeting, Government, Remuneration, Mineral, News, Security (finance), Points of the compass

Following the meeting, David Moore tendered his resignation from the Board but will continue as Interim President and CEO.

Key Points: 
  • Following the meeting, David Moore tendered his resignation from the Board but will continue as Interim President and CEO.
  • On Behalf of the Board of Directors of NorthWest Copper Corp.
  • Although NorthWest believes that the expectations reflected in such forward-looking information and/or information are reasonable, undue reliance should not be placed on forward-looking information since NorthWest can give no assurance that such expectations will prove to be correct.
  • NorthWest does not undertake any obligation to update forward-looking information except as required by applicable securities laws.

Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023

Retrieved on: 
Wednesday, September 20, 2023
Deformity, Surgeon, American Orthopaedic Foot and Ankle Society, Social, Annual, NUALS Arts and Literary Annual Meet, MD–MS program, Instrument, Trial of the century, Recurrence, Patient, Manuscript, Hammer toe, MD, Bunion, Poster, HVA, Micro, Dissection, Pharmaceutical industry, Nursing, Medical device, Medical imaging

The Micro-Lapiplasty™ System is currently in limited clinical release with full commercial launch expected in the fourth quarter of this year.

Key Points: 
  • The Micro-Lapiplasty™ System is currently in limited clinical release with full commercial launch expected in the fourth quarter of this year.
  • Additionally, at 36 months post-procedure, less than 5% of patients were unsatisfied with the overall results of the procedure (n=96).
  • The poster, which includes additional details, can be accessed by AOFAS meeting attendees on a kiosk at the Annual Meeting or on the mobile app.
  • The Company plans to submit its primary endpoint ALIGN3D™ manuscript for publication in a top-tier peer-reviewed foot and ankle journal later in 2023.

Nano Dimension Reminds Shareholders to Protect Their Investment and VOTE TODAY FOR Its Highly Qualified Nominees

Retrieved on: 
Wednesday, August 30, 2023
Nano, ALL, 3D, NUALS Arts and Literary Annual Meet, Electronics, NO, Annual general meeting, Growth, 3D printing, Management, Security (finance), Video game, Holding company, Internet service provider

Waltham, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension”, “Nano”, or the “Company”), a leading supplier of Additively Manufactured Electronics and multi-dimensional polymer, metal & ceramic Additive Manufacturing 3D printers, today reminded shareholders that the deadline to vote at the Company’s 2023 Annual General Meeting (“Annual Meeting”) is fast approaching. Shareholders are encouraged to vote by 11:59 p.m. ET on August 30th, 2023, to ensure their votes are counted.

Key Points: 
  • Nano Dimension’s Board of Directors (“the Board”) unanimously recommends that shareholders protect their investment and vote “FOR” ALL of Nano’s highly qualified nominees today.
  • Our strategy includes disciplined M&A of transformative and highly accretive opportunities and strong organic growth from leading technology development and innovation efforts.
  • Shareholders of record as of the close of business on July 31st, 2023, are entitled to vote at the meeting.
  • Since time is short, shareholders are encouraged to VOTE today by e-mail or electronically according to the instructions on their proxy card.